Search

everythinglearnresearchcommunity

for

Search:↓

ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.

Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

PLD is an effective and safer alternative for treating breast cancer.

Some breast cancer chemotherapy can cause permanent hair loss.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

No definitive link between finasteride and male breast cancer, but further research is needed.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.

Finasteride use may increase the risk of male breast cancer.

Finasteride use is not clearly linked to an increased risk of male breast cancer.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Understanding breast cancer requires considering both medical advancements and social influences.

Pranic meditation significantly improved mental health and quality of life for breast cancer survivors.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.